We want more people to have access to good treatment and innovative solutions that contribute to better quality of life, health and well-being. Tomorrow’s welfare society requires an accessible and more sustainable healthcare system, where ideas and technology based on high scientific quality can create value, growth and care.
The following is a selection of our investments in effective healthcare for more people:
p53 invests in healthcare companies that are rethinking and challenging the status quo. The company wants to contribute to the development and commercialisation of groundbreaking ideas that will increase the availability of better treatments and innovative services with a particularly positive effect on people’s lives and health.
p53 works closely with entrepreneurs to build competitive healthcare companies. In addition to long-term capital, the investment company contributes value in the form of knowledge, experience and networks through active ownership.
Nyby has developed a digital platform for resource collaboration. This helps free up the time of health professionals while helping the health and care sector create more and better services, reduce loneliness and be more inclusive.
The service is well established in the Norwegian market, where Norwegian municipalities and organisations use it for tasks and assignment sharing. Some of the needs facilitated are assistance with errands, practical help, attending medical appointments with the patient, exercise and social activities. Unlike much other welfare technology, Nyby is not a tool for replacing people, but for connecting them.
Resani develops disinfection technology that helps health professionals, patients, visitors and others massively improve their hand hygiene.
The goal is to reduce the incidence of infections and disease transmission from poor hand hygiene.
Through its patent-pending combination of user reflex, software and hardware, Resani enables you to comply with good hand hygiene in less than five seconds. At the same time, user data will provide useful analytics and valuable insights for organisations and institutions.
Arctoris has developed its own technology platform to facilitate data-centric development of pharmaceuticals.
The company aims to contribute to the development of new and better treatments for millions of people suffering from chronic diseases. Arctoris combines robotics, computer science and machine learning to make decisions based on reliable and reproducible data. Advanced calculations, together with a world-class team, drive development forward.
Nykode Therapeutics is a Norwegian biopharmaceutical company dedicated to developing new immunotherapy to combat cancer, infectious diseases and autoimmune conditions.
The company is developing groundbreaking, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Nykode’s unique modular technology platform is designed so that the active substances are directed to those cells in the body that are optimal for initiating fast, strong and long-lasting immune responses. The overall goal is to reduce the impact of disease on people’s lives.